Entrust Financial’s Quest Diagnostics DGX Stock Holding History

Entrust Financial’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.45K	Hold	21	–	–	﹤0.01%	371
2026 Q1	$4.12K	Hold	21	–	–	﹤0.01%	370
2025 Q4	$3.65K	Buy	+21	New	+$3.82K	﹤0.01%	372

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Entrust Financial's DGX Position: Q2 2026 in Review

Entrust Financial held its Quest Diagnostics (DGX) position steady in Q2 2026 at 21 shares worth $4.45K. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Entrust Financial first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 1,103 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Entrust Financial held 21 shares of Quest Diagnostics worth $4.45K as of Q2 2026.
Entrust Financial left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Entrust Financial's portfolio in Q2 2026, its #371 holding.
Entrust Financial first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
1,103 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Entrust Financial's 13F filing for Q2 2026, filed 20 Jul 2026.